D
Adverum Biotechnologies, Inc. ADVM
$4.20 $0.030.72% NASDAQ
Recommendation
Prev Close
$4.17
Volume
1,077,362
Avg Vol (90D)
504,556
Market Cap
$92.06M
Dividend & Yield
--
52-Week Range
$1.78 - $6.45
P/E (TTM)
--
EPS (TTM)
-$9.51
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock
12/4/2025 - Zacks Investment Research
Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Braden Michael Leonard Sells 51,961 Shares of Stock
12/4/2025 - Ticker Report
Braden Michael Leonard Sells 222,925 Shares of Adverum Biotechnologies (NASDAQ:ADVM) Stock
12/4/2025 - MarketBeat
Eli Lilly (LLY) Sets Tender Offer to Acquire Adverum Biotechnologies
12/1/2025 - GuruFocus
Adverum Biotechnologies reminds stockholders to tender their shares
12/1/2025 - TipRanks Financial Blog
Adverum Biotechnologies reminds stockholders to tender their shares
12/1/2025 - The Fly
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly
12/1/2025 - Globe Newswire
Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally
11/24/2025 - Zacks Investment Research
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Rating of "Hold" from Analysts
11/23/2025 - MarketBeat
Adverum Biotechnologies Faces Lease Termination Notice
11/21/2025 - TipRanks Financial Blog
Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales
11/20/2025 - Zacks Investment Research
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
11/19/2025 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOUS, ADVM, HBAN, and COMP
11/19/2025 - PR Newswire
Halper Sadeh LLC Encourages CMA, ADVM, HOUS Shareholders to Contact the Firm to Discuss Their Rights
11/19/2025 - Globe Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers HOUS, ADVM, HBAN, and COMP
11/18/2025 - Globe Newswire
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
11/18/2025 - Zacks Investment Research
The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum
11/18/2025 - Zacks Investment Research
Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ
11/17/2025 - Zacks Investment Research
Mizuho Securities Remains a Buy on Adverum Biotechnologies (ADVM)
11/17/2025 - TipRanks Financial Blog
Adverum Biotechnologies downgraded to Neutral from Buy at H.C. Wainwright
11/17/2025 - TipRanks Financial Blog
Adverum Biotechnologies just downgraded at H.C. Wainwright, here's why
11/17/2025 - The Fly
Adverum Biotechnologies, Inc. $ADVM is BML Capital Management LLC's 7th Largest Position
11/17/2025 - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Announces Earnings Results, Misses Expectations By $0.23 EPS
11/14/2025 - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Announces Earnings Results, Misses Expectations By $0.23 EPS
11/13/2025 - Ticker Report
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Nov 2025)
11/12/2025 - 24/7 Wall St.
Income Statement
Total Revenue (TTM)
$0.00
EBITDA (TTM)
-$205.82M
EBIT (TTM)
-$208.32M
Net Income (TTM)
-$204.39M
Balance Sheet
Total Assets (Q)
$72.40M
Total Debt (Q)
$88.94M
Total Liabilities (Q)
$128.05M
Book Value Per Share (Q)
-$2.53
Cash Flow
Cash from Operations (TTM)
-$137.90M
Cash from Investing (TTM)
$60.85M
Cash from Financing (TTM)
$10.26M
Net Change in Cash (TTM)
-$66.79M
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Apr 13 and 17 (est)
Price History
Loading...
Beta
0.49
7-Day Total Return
1.94%
30-Day Total Return
-1.17%
60-Day Total Return
26.89%
90-Day Total Return
70.04%
Year to Date Total Return
-12.50%
1-Year Total Return
-30.00%
2-Year Total Return
-52.33%
3-Year Total Return
-36.35%
5-Year Total Return
-96.94%
52-week Low
May 15, 2025 - $1.78
52-week High
Dec 04, 2024 - $6.45
Valuation
Market Cap
$92.06M - Micro Cap
Enterprise Value
$154.94M
Price/Sales (TTM)
--
Price/Book (Q)
-1.65
Dividends and Shares
Shares Outstanding
23.49
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
adverum.com
Phone Number
650 656 9323
Address
100 Cardinal Way
Redwood City, CA 94063
Country
United States
Year Founded
2006
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a... more
NASDAQ 12/04/2025 2:15PM Eastern Quotes delayed